Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Anticholinergic drugs may not be effective in treating MS urinary symptoms

  • Comment
A Cochrane review have suggested that there is insufficient evidence to support the use of anticholinergic drugs to treat urinary symptoms in patients with multiple sclerosis (MS)
Anticholinergic drugs (antimuscarinics) areused to treaturgency and urge incontinence by reducing involuntary bladder contractions and increase bladder capacity. Around 68% of people with MS report urinary symptoms.

The Cochrane review included three randomised controlled trials. The first trail included 34 people with MS and researchers evaluated the effect of three drugs; methantheline bromide, flavoxate chloride and meladrazine tartrate.

The second study included 34 people who were treated with oxybutynin or propantheline.

Sixty-four people were included in the third trial and they were prescribed oral oxybutynin or atropine administered directly in to the bladder.

The authors of the review concluded that the current evidence does not support the use of anticholinergic drugs in the treatment of people with MS who have urinary symptoms.

Further reading:

Managing bladder symptoms in people with multiplesclerosis

MS patients still missing out on services

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.